---
title: "Kisspeptin-54 (Metastin)"
canonical_url: https://peptidelibrary.app/library/kisspeptin-54
description: "Full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis. It acts on hypothalamic neurons upstream of GnRH release and is a gatekeeper of puberty and reproductive axis function; loss-of-function mutations in its receptor cause failure of puberty. It has been used in human reproductive-endocrine research, where its longer sequence gives a somewhat greater duration of action than kisspeptin-10. Not FDA-approved. Prohibited in sport under WADA class S2."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Kisspeptin-54 (Metastin)

Kisspeptin-54 (Metastin), also called Kp-54, is a research peptide in the GnRH Modulator class. Kisspeptin-54 is the full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis.

Full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis. It acts on hypothalamic neurons upstream of GnRH release and is a gatekeeper of puberty and reproductive axis function; loss-of-function mutations in its receptor cause failure of puberty. It has been used in human reproductive-endocrine research, where its longer sequence gives a somewhat greater duration of action than kisspeptin-10. Not FDA-approved. Prohibited in sport under WADA class S2.

Also known as: Kp-54.

Categories: Experimental.

## Classification

- Type: Full-length kisspeptin / research
- Mechanism class: GnRH Modulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Kisspeptin-54 is the full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis. It acts at KISS1R on hypothalamic GnRH neurons, the signalling step that gates the entire reproductive axis: loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism and failure of puberty, which is what established kisspeptin as the upstream trigger of GnRH pulsatility. Receptor activation depolarises GnRH neurons and increases luteinising and follicle-stimulating hormone secretion. The longer full-length peptide has a somewhat greater duration of action than the kisspeptin-10 fragment, though both are short-lived.

Targets: KISS1R.

Origin: Synthetic full-length kisspeptin-54.

## Properties

- Molecular formula: C258H401N79O78
- Molecular weight: ≈5857 g/mol
- CAS number: 374675-16-8
- Half-life: Short; study-dependent
- Studied routes: Subcutaneous, Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 2
- Controlled human trials: 0
- Preclinical sources: 0
- Latest source: 2025

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women. Clin Endocrinol (Oxf). 2016. 2016. Human study (early or uncontrolled). Population: Healthy women (n=4), early follicular phase across 4 separate menstrual cycles. Luteinising hormone and gonadotrophin release, and its relationship to baseline oestradiol [Source](https://pubmed.ncbi.nlm.nih.gov/26572695/)
2. Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans. J Clin Endocrinol Metab. 2025. 2025. Human study (early or uncontrolled). Population: Human participants. Reproductive hormones and anxiety measures [Source](https://pubmed.ncbi.nlm.nih.gov/40036336/)

## Safety

Side effects: Injection reactions; Reproductive-hormone swings.

Risks: WADA S2.

Human safety basis: Limited human reports

Key limitations: No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Kisspeptin-54 (Metastin) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Kisspeptin-54 (Metastin)?

Full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis. It acts on hypothalamic neurons upstream of GnRH release and is a gatekeeper of puberty and reproductive axis function; loss-of-function mutations in its receptor cause failure of puberty. It has been used in human reproductive-endocrine research, where its longer sequence gives a somewhat greater duration of action than kisspeptin-10. Not FDA-approved. Prohibited in sport under WADA class S2.

### How does Kisspeptin-54 (Metastin) work?

Kisspeptin-54 is the full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis. It acts at KISS1R on hypothalamic GnRH neurons, the signalling step that gates the entire reproductive axis: loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism and failure of puberty, which is what established kisspeptin as the upstream trigger of GnRH pulsatility.

### Is Kisspeptin-54 (Metastin) FDA approved?

No. Kisspeptin-54 (Metastin) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Kisspeptin-54 (Metastin)?

Reported half-life for Kisspeptin-54 (Metastin) is Short; study-dependent. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Kisspeptin-54 (Metastin) banned in sport?

Kisspeptin-54 (Metastin) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Kisspeptin-54 (Metastin)?

Compounds most often compared with Kisspeptin-54 (Metastin) include Kisspeptin-10, Gonadorelin, Cetrorelix and Degarelix. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Circulatory metastin/kisspeptin-1 in polycystic ovary syndrome: a systematic review and meta-analysis with diagnostic test accuracy — Reprod Biomed Online, 2019](https://pubmed.ncbi.nlm.nih.gov/31515170/)
- [Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog — Int J Toxicol, 2021](https://pubmed.ncbi.nlm.nih.gov/34126799/)
- [Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders — J Clin Invest, 2020](https://pubmed.ncbi.nlm.nih.gov/33196464/)
- [Distribution of the kisspeptin system and its relation with gonadotropin-releasing hormone in the hypothalamus — Vitam Horm, 2025](https://pubmed.ncbi.nlm.nih.gov/39864946/)
- [Kisspeptin system-physiology and clinical perspectives — Ann Endocrinol (Paris), 2025](https://pubmed.ncbi.nlm.nih.gov/40446957/)
